| Sustained effects of recombinant GH replacement after 7 years of treatment in adults with GH deficiency. | |
| | |
MedLine Citation:
|
PMID: 17062886 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
CONTEXT: The goal of GH replacement with recombinant human GH (rhGH) is to ameliorate symptoms, signs, and complications of adult GH deficiency (GHD) in the long term. To determine whether the observed short-term beneficial effects of rhGH treatment are sustained in the long term, we evaluated biochemical and anthropometric parameters after 7 years of rhGH replacement. PATIENTS AND METHODS: After 2, 5, and 7 years of rhGH replacement, 63 adult GHD patients (30 men, 52 adult-onset GHD) were assessed. IGF-I increased during rhGH replacement, and a stable dose of rhGH was reached within 1 year of rhGH substitution. Thereafter, this individualized dose was continued. RESULTS: Plasma levels of total cholesterol and low-density lipoprotein cholesterol decreased even after 5 years of rhGH replacement (11% decrease, P < 0.001; 22% decrease, P < 0.001 respectively). High-density lipoprotein cholesterol levels increased during 7 years of rhGH replacement (1.4 +/- 0.5 mmol/l at baseline vs 1.7 +/- 0.5 mmol/l after 7 years, P < 0.001), whereas triglyceride concentrations remained unchanged. Fasting glucose levels increased during follow-up, mainly during the first 2 years of rhGH replacement (4.4 +/- 0.7 mmol/l to 5.0 +/- 1.0 mmol/l, P < 0.001). Body mass index increased during follow-up, whereas waist circumference and waist-to-hip ratio remained unchanged. Diastolic blood pressure decreased (P = 0.002), but when patients using antihypertensive medication were excluded this decrease did not reach significance (P = 0.064). Systolic blood pressure remained unchanged. CONCLUSION: The beneficial effects of rhGH replacement, described after short-term rhGH replacement, are sustained in the long term up to 7 years. |
| | |
Authors:
|
A A van der Klaauw; J A Romijn; N R Biermasz; J W A Smit; J van Doorn; O M Dekkers; F Roelfsema; A M Pereira |
Related Documents
:
|
22725706 - Position of indapamide, a diuretic with vasorelaxant activities, in antihypertensive th... 1596306 - Microalbuminuria and associated cardiovascular risk factors in the community. 8533746 - Spouse correlations in cardiovascular risk factors and the effect of marriage duration. 8324436 - Effectiveness of programme for reducing cardiovascular risk for men in one general prac... 6111636 - Pressor effect of naloxone in septic shock. 8223806 - The effect of variations in positive end expiratory pressure on gas exchange in ventila... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: European journal of endocrinology / European Federation of Endocrine Societies Volume: 155 ISSN: 0804-4643 ISO Abbreviation: Eur. J. Endocrinol. Publication Date: 2006 Nov |
Date Detail:
|
Created Date: 2006-10-25 Completed Date: 2007-01-08 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9423848 Medline TA: Eur J Endocrinol Country: England |
Other Details:
|
Languages: eng Pagination: 701-8 Citation Subset: IM |
Affiliation:
|
Department of Endocrinology and Metabolic Diseases C4-R, Leiden University Medical Center, Po Box 9600, 2300 RC, Leiden, The Netherlands. a.a.van_der_klaauw@lumc.nl |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Age Factors Blood Glucose / metabolism Body Mass Index Cholesterol / blood Cholesterol, HDL / blood Cholesterol, LDL / blood Fasting / blood Female Follow-Up Studies Human Growth Hormone / deficiency, therapeutic use* Humans Male Middle Aged Prospective Studies Recombinant Proteins / therapeutic use Sex Factors Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Blood Glucose; 0/Cholesterol, HDL; 0/Cholesterol, LDL; 0/Recombinant Proteins; 12629-01-5/Human Growth Hormone; 57-88-5/Cholesterol |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Biochemical markers of bone turnover and their relation to forearm bone mineral density in persons o...
Next Document: Serum GH and IGF-I are significant determinants of bone turnover but not bone mineral density in act...